Navigation Links
IRIDEX Reports First Quarter 2009 Financial Results

MOUNTAIN VIEW, Calif., May 14 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first quarter of 2009 ended April 4, 2009.

For the first quarter of 2009 the Company recorded a net profit of $0.2 million or $0.03 per diluted share compared to a net loss of $0.9 million or $0.10 per diluted share in the first quarter of 2008. Revenue for the first quarter of 2009 was $10.7 million, a 6.4% decrease from the $11.5 million reported for the first quarter of 2008.

Ophthalmology revenues were $7.5 million in the first quarter of 2009 consistent with $7.5 million for the comparable period in 2008. Ophthalmology recurring revenues, comprised of consumable products and service were $4.4 million for the first quarter of 2009, up 6.7% from $4.2 million for the first quarter 2008.

Total Aesthetics revenues were $3.2 million in the first quarter of 2009 compared with $3.9 million in the comparable period of 2008, a decrease of 18.9%.

Gross profit for the first quarter of 2009 was $5.0 million, compared with $4.8 million for the first quarter of 2008. Gross margins were 47.0% and 41.9% for the first quarter of 2009 and 2008, respectively, an improvement of 5.1% of revenues. Operating expenses for the first quarter 2009 were $4.7 million compared with $5.5 million for 2008, or 43.6% and 48.3% of revenues, respectively.

"Returning to profitability given the current distressed economic environment represents a major accomplishment for the company," stated Mr. Theodore A. Boutacoff, President and CEO. "This is the first quarter that we have been profitable on an operating income level since the fourth quarter of 2005. Keys to achieving profitability during the quarter were improvement in our gross margins to 47% of revenues and managing our operating expenses exceptionally well.

"Our profitable performance during the first quarter reflects steady progress towards successfully implementing our strategic objectives," Mr. Boutacoff continued, "which are: continuing to manage the Company to be cash flow positive while driving profitability; putting the majority of our focus on our Ophthalmology business and looking to invest in growth opportunities for Ophthalmology.

"During the first quarter our financial strength continued to improve with $0.9 million in cash generated from operations which allowed us to increase our cash balance and at the same time start reducing our bank debt; as a result we now have cash in excess of our debt," continued Mr. Boutacoff. "We believe our strategy of continuing to focus on our Ophthalmology business is bearing fruit. Our Ophthalmology recurring revenues have grown quarter over comparable quarter even in these tough times. Furthermore, we announced that the first shipment of the IQ 577, our high-power, true yellow (577 nm wavelength) laser system for use by ophthalmologists was shipped in April for commercial sale, and we see the addition of the IQ 577 to our Ophthalmology product line as reinforcement of the IRIDEX brand for high quality technically advanced Ophthalmology products."

Cash and cash equivalents were $5.7 million as of April 4, 2009, up from $5.3 million in January 3, 2009, while bank debt was $5.5 million as of April 4, 2009, down from $6.0 million as of January 3, 2009.

Conference Call

IRIDEX management will conduct a conference call later today, Thursday, May 14, 2009 at 5:00 p.m. Eastern Time. Interested parties may access the live conference call via telephone by dialing (877) 941-9205 (U.S.) or (480) 629-9041 (International) and quoting Conference ID 4075884, or by visiting the Company's website at A telephone replay will be available beginning on Thursday, May 14, 2009 through Thursday, May 21, 2009 by dialing (800) 406-7325 (U.S.) or (303) 590-3030 (International) and entering Access Code 4075884. In addition, later today an archived version of the webcast will be available on the Company's website at


IRIDEX Corporation is a leading worldwide provider of therapeutic based laser systems, consumable laser probes and delivery devices used to treat eye diseases in ophthalmology and skin conditions in the aesthetics market. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 100 independent distributors into 107 countries. For further information, visit the Company's website at

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Act of 1934, as amended, relating to the Company's financial stability, growth strategy and prospects. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended January 3, 2009 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

                               IRIDEX Corporation
                   Condensed Consolidated Statements of Operations
                     (In thousands, except pet share data)
                                                     Three Months Ended
                                                    April 4,   March 29,
                                                      2009       2008
                                                      ----       ----

    Revenues                                        $10,736    $11,474
    Cost of revenues                                  5,688      6,669
                                                      -----      -----
        Gross profit                                  5,048      4,805
                                                      -----      -----

    Operating expenses:
      Research and development                          841      1,025
      Sales and marketing                             2,351      2,613
      General and administrative                      1,493      1,905
                                                      -----      -----
        Total operating expenses                      4,685      5,543
                                                      -----      -----

    Income (loss) from operations                       363       (738)

      Interest and other expense, net                  (139)      (154)
                                                       ----       ----
    Income (loss) before income taxes                   224       (892)
      Provision for income taxes                          -          -
                                                        ---        ---
    Net income (loss)                                  $224      $(892)
                                                       ====      =====

    Net income (loss) per share -
     basic and diluted                                $0.03     $(0.10)
                                                      =====     ======

    Shares used in computing net income (loss) per
     share - basic and diluted                        8,825      8,824
                                                      =====      =====

                               IRIDEX Corporation
                       Condensed Consolidated Balance Sheets
                                  (In thousands)
                                                        April 4,   January 3,
                                                          2009        2009
                                                          ----        ----
                        Assets                        (unaudited)
    Current Assets:
      Cash and cash equivalents                         $5,662      $5,307
      Accounts receivable, net                           7,809       8,199
      Inventories, net                                  11,164      11,644
      Prepaids and other current assets                    516         540
                                                           ---         ---
        Total current assets                            25,151      25,690
       Property and equipment, net                         710         832
       Other intangible assets, net                      1,394       1,474
       Other long term assets                              310         229
                                                           ---         ---
        Total assets                                    27,565      28,225
                                                        ======      ======

         Liabilities and Stockholders' Equity
    Current Liabilities:
      Accounts payable                                  $1,951      $2,415
      Bank line of credit                                5,477       6,000
      Accrued compensation                               1,823       1,729
      Accrued expenses                                   2,151       2,249
      Accrued warranty                                   1,294       1,345
      Deferred revenue                                   2,733       2,741
      Bank term loan                                         -           -
                                                             -           -
        Total current liabilities                       15,429      16,479
                                                        ------      ------

    Stockholders' Equity:
      Convertible preferred stock                            5           5
      Common Stock                                          89          89
      Additional paid-in capital                        39,244      39,105
      Accumulated other comprehensive loss                (165)       (192)
      Treasury stock, at cost                             (430)       (430)
      Accumulated deficit                              (26,607)    (26,831)
                                                       -------     -------
        Total stockholders' equity                      12,136      11,746
                                                        ------      ------
        Total liabilities and stockholders' equity     $27,565     $28,225
                                                       =======     =======

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. IRIDEX Announces First Quarter 2009 Conference Call and Release Date
2. IRIDEX Announces Shipment of New IQ 577(TM) Laser Systems
3. IRIDEX Reports Fourth Quarter and Full Year 2008 Financial Results
4. IRIDEX Announces Fourth Quarter and Full Year 2008 Conference Call and Release Date
5. IRIDEX Reports Third Quarter 2008 Financial Results
6. IRIDEX Announces Third Quarter 2008 Conference Call and Release Date
7. IRIDEX Reports First Quarter 2008 Financial Results
8. IRIDEX Announces First Quarter 2008 Conference Call and Release Date
9. IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results
10. IRIDEX Announces Fourth Quarter and Full Year 2007 Conference Call and Release Date
11. IRIDEX Reports Third Quarter Financial Results
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions announced ... User Group (MSDSLUG). Recognized as Microsoft’s official group for end users of Dynamics ... software users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates their ...
(Date:11/27/2015)... ... 2015 , ... The men and women on this list ... the country. They have overseen financial turnarounds, shown commitment to their community through ... as a whole through their advocacy and professional efforts. , Becker's Hospital Review ...
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think Thanksgiving, they also ... buy during the Black Friday and Cyber Monday massage chair sales to ... Internet high and low to find the best massage chair deals, they can see ...
(Date:11/26/2015)... ... 2015 , ... PRMA Plastic Surgery is updating their record books yet again ... free flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, says ... and it’s an honor to have served all of these women.” , PRMA is ...
(Date:11/25/2015)... OAK BROOK, Ill. (PRWEB) , ... November 25, ... ... sometimes larger and potentially more aggressive than those found on mammography, according to ... cases MRI findings of additional cancers not seen on mammography may necessitate a ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
(Date:11/25/2015)... MINNEAPOLIS , Nov. 25, 2015  ARKRAY ... care products, continues to provide evidence demonstrating the accuracy ... the World Congress on Insulin Resistance, Diabetes and Cardiovascular ... showed that both the Company,s GLUCOCARD ® 01 ... met high accuracy requirements. The ability to accurately measure ...
Breaking Medicine Technology: